SCHEMBL4313230

SCHEMBL4313230

O=C(OC(Cn1ncnn1)c1ccccc1Cl)N1CCN(Cc2ccccc2)CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.43
MEN1 O00255 2/20 0.43
ALDH1A1 P00352 5/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
MGLL Q99685 2/20 0.41
PLA2G7 Q13093 1/20 0.41
ABHD6 Q9BV23 1/20 0.41
FAAH O00519 2/20 0.40
PKM P14618 1/20 0.40
MAPK1 P28482 1/20 0.40
LMNA P02545 2/20 0.40
MAPT P10636 2/20 0.40
POLB P06746 2/20 0.40
NPC1 O15118 1/20 0.40
MITF O75030 1/20 0.40
S1PR4 O95977 1/20 0.40
S1PR1 P21453 1/20 0.40
HTT P42858 1/20 0.40
RECQL P46063 1/20 0.40
RAB9A P51151 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4304707 0.87 KMT2A (0.40) KMT2AMEN1ALDH1A1SMN1; SMN2MGLL
SCHEMBL4306732 0.86 FAAH (0.47) KMT2AMEN1ALDH1A1SMN1; SMN2FAAH
SCHEMBL13667456 0.86 FAAH (0.47) KMT2AMEN1ALDH1A1SMN1; SMN2FAAH
SCHEMBL13667455 0.86 FAAH (0.47) KMT2AMEN1ALDH1A1SMN1; SMN2FAAH
SCHEMBL4318842 0.83 MGLL (0.42) KMT2AMEN1ALDH1A1MGLLPOLB
SCHEMBL4311381 0.83 POLB (0.39) MGLLPLA2G7ABHD6FAAHPKM
SCHEMBL4306705 0.81 SPR (0.44) FAAHPKMPOLBCYP2C9CYP2C19
SCHEMBL4313590 0.81 POLB (0.37) KMT2AMEN1POLB
SCHEMBL4309032 0.81 FAAH (0.41) KMT2AMEN1ALDH1A1MGLLFAAH
SCHEMBL4315951 0.80 POLB (0.37) MGLLFAAHPKMPOLBCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1879873-B1 NEUROTHERAPEUTIC AZOLE COMPOUNDS SK BIOPHARMACEUTICALS CO LTD (KR) 2013-10-09 EP disclosed
US-7598279-B2 Neurotherapeutic azole compounds SK HOLDINGS CO., LTD. (KR) 2009-10-06 US disclosed
US-7598279-B2 Neurotherapeutic azole compounds SK HOLDINGS CO., LTD. (KR) 2009-10-06 US disclosed
EP-1879873-A1 NEUROTHERAPEUTIC AZOLE COMPOUNDS SK Holdings Co., Ltd. (KR) 2008-01-23 EP disclosed
US-20060258718-A1 Neurotherapeutic azole compounds SK BIOPHARMACEUTICALS CO., LTD. (KR) 2006-11-16 US disclosed
WO-2006112685-A1 NEUROTHERAPEUTIC AZOLE COMPOUNDS SK HOLDINGS CO., LTD. (KR) 2006-10-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060258718-A1 Neurotherapeutic azole compounds CHRNA10, CHRNA4, CHRNA3 KMT2A 1096/4885MEN1 1549/4885ALDH1A1 1039/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.